Becton Dickinson and Co (NYSE:BDX) has been given an average rating of “Buy” by the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $266.40.
Several analysts have recently weighed in on BDX shares. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Barclays raised shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 target price on the stock in a report on Monday, May 13th. Piper Jaffray Companies lowered their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, KeyCorp reaffirmed an “overweight” rating and issued a $262.00 target price (down previously from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th.
In related news, EVP Patrick Kaltenbach sold 275 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $235.00, for a total value of $64,625.00. Following the completion of the sale, the executive vice president now owns 16,482 shares in the company, valued at $3,873,270. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 1,429 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,444 shares of company stock worth $2,061,288. Insiders own 0.12% of the company’s stock.
Becton Dickinson and stock traded down $2.20 during midday trading on Tuesday, hitting $249.28. 902,000 shares of the company’s stock were exchanged, compared to its average volume of 1,204,034. Becton Dickinson and has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a debt-to-equity ratio of 0.84, a quick ratio of 0.67 and a current ratio of 1.09. The stock has a market cap of $68.01 billion, a price-to-earnings ratio of 22.64, a price-to-earnings-growth ratio of 1.80 and a beta of 1.11. The firm’s 50 day simple moving average is $251.74 and its 200 day simple moving average is $244.37.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The company had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period last year, the firm posted $2.91 EPS. Becton Dickinson and’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, equities research analysts forecast that Becton Dickinson and will post 11.68 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.24%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s payout ratio is 27.97%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.